Tenofovir DF- Warning!

If you have both HIV and hepatitis B virus (HBV) infection and take tenofovir DF, your HBV infection may get much worse (flare up) if you stop taking tenofovir DF. Talk to your health care provider about taking an HBV test before you start tenofovir DF for the treatment of HIV. You should take an HIV test if you are taking tenofovir DF for the treatment of chronic HBV. The HBV drug adefovir dipivoxil (brand name: Hepsera) should not be taken with tenofovir DF.

While taking tenofovir DF, it is important to keep all of your appointments with your health care provider.

If you miss a dose of tenofovir DF, take the missed dose as soon as you remember it. But if it is almost time for your next dose, skip the missed dose and just take your next dose at the regular time. Do not take two doses at the same time to make up for a missed dose.Tenofovir DF is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in adults and children 2 years of age and older. Tenofovir DF is always used in combination with other HIV medicines.

Tenofovir disoproxil fumarate (tenofovir DF) can cause serious, life-threatening side effects. These include a buildup of lactic acid in the blood (lactic acidosis) and severe liver problems.

Tags:the treatment,terapy,Tenofovir DF,HIV,

Pegasys interferon therapy II

Sustained Response in HBeAg Negative Chronic Hepatitis B Patients 3 Years After Treatment with Pegasys

Investigators with the international Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group randomly assigned more than 500 HBeAg negative chronic hepatitis B patients to received 180 mcg/week pegylated interferon monotherapy, 100 mg/day lamivudine (Epivir) monotherapy, or the same doses of both drugs used in combination, all for 48 weeks.
The researchers previously reported that HBeAg negative patients treated with pegylated interferon, with or without lamivudine, achieved significantly higher rates of sustained response 6 months after completing therapy than individuals treated with lamivudine alone.

In the present analysis, the authors looked at long-term durability though 3 years after treatment completion. A total of 315 patients (59% of the original patient population) participated in the post-treatment observational study.
Results

	-3 years after treatment, 28% of patients treated with pegylated interferon (with or without lamivudine) had HBV DNA levels <10,000 copies/mL, compared to 15% of patients treated with lamivudine monotherapy (P = 0.039).
	-Similarly, more patients treated with pegylated interferon had normal alanine aminotransferase (ALT) at the end of follow-up compared to those treated with lamivudine monotherapy (31% vs 18%; P = 0.032).
	-Use of pegylated interferon and high baseline ALT were independent predictors of long-term virological response (P = 0.040 and 0.01, respectively).
	-Among participants treated with pegylated interferon (again, with or without lamivudine), 8.7% overall -- or 44% of those with undetectable HBV at the end of follow-up -- cleared hepatitis B surface antigen (HBsAg), versus none treated with lamivudine monotherapy.

Based on these findings, the study authors concluded, "Biochemical and virologic responses were sustained for <3 years in approximately 25% of patients given a 48-week course of peginterferon alpha-2a, with or without lamivudine."
In their discussion, they added, "The ability to induce HBsAg clearance -- an outcome that is associated with long-term complication-free survival -- supports the use of peginterferon alfa-2a as a first-line treatment of HBeAg negative disease, avoiding the need for long-term therapy and the associated risks of developing drug resistance in those patients who achieve and maintain their response."
Drug resistance is a known risk with lamivudine and other nucleoside/nucleotide analogs that directly target HBV. Interferon is less likely to be limited by resistance since it promotes immune response against HBV rather than interfering directly with the viral life-cycle.
tags:Pegasys interferon therapy,Similarly,HBeAg negative disease

My diagnosed hepatitis C treatment

My diagnosed hepatitis C  treatment

Diagnosed 1992
Pegintron treatment 2004 unsucessful
Genotype 1b
FibroScan 10 (F2)
Start Viekira 10.17.2015
Viekira is used to treat chronic hepatitis C in adults. It is sometimes given in combination with another antiviral medicine called ribavirin.

AST 49 ALT 76
VL 440k
10.31.2015/Week 2 Labs : AST 14/ALT 17
No VL done
10.14.2015/Week 4 labs : AST 14/ALT 14
VL UNDETECTED!!!
12.11.2015/Week 8 Labs : AST 12/ALT 13
No VL done
01.05.2016/EOT labs : AST 15/ALT 13
VL UNDETECTED!!!

12 WEEK SRV:UN-BLOODY DETECTABLE !!!!!!!!

24 WEEK SVR:UNDETECTABLE!!!! 

He did not come back,yeeees!

Viekira is an antiviral medicine containing a combination of dasabuvir, ombitasvir, paritaprevir, and ritonavir. Dasabuvir, ombitasvir, paritaprevir, and ritonavir are antiviral medicines that prevent the hepatitis C virus (HCV) from multiplying in your body.



tags:diagnosed.treatment,hepatitis C,viekira,

The first sign of liver disease

The first sign of liver disease, that is Jaundice (Yellowish discoloration of the sclera of the eyes) due to accumulation of bilirubin, occurs with bilirubin range of 2-3 mg/d. Skin discoloration occurs at much higher levels. 

Some general some symptoms of liver disease include nausea, vomiting, decreased appetite, ‎indigestion, change in stools, jaundice, itching, etc. ‎In severe conditions with greater liver dysfunction abdominal distension, swelling of the legs, ‎anorexia, lethargy could be evident. 

Bilirubin is an excretion product, and levels found in the body reflects the balance between ‎production and excretion. ‎ 

The normal range of Total serum bilirubin lies in the range of 0.1 - 1.2 mg/ Dl. 

But in the determination of any liver conditions, just elevated bilirubin or liver enzymes levels are not significant. 

If you do not have any other signs and symptoms other than the yellowish discoloration of your eye then it would be insignificant and you need not worry about it. 

Tags:disease,the liver,bilirubin,symptoms,

Hepatitis - forums?

Living with hepatitis forum:

hepatitis I

hepatitis II forum

hepatitis-liver forum III

forum on hepatitis

hepatitis forums

 One of the safest dietary practices for someone with a diseased liver is to avoid additional toxins such as alcohol, alternative remedies that are unknown to science and all recreational drugs

Some forms of hepatitis will develop into a chronic disease, usually when the infection has been longer than 6 months.

tag:liver,hepatitis ABCD,virus,

MS - Multiple sclerosis II

Multiple sclerosis:Two new trials show,the cancer drug alemtuzumab (Campath) reduces the risk of disease relapse in people with multiple sclerosis.British researchers led by Alastair Compston of the University of Cambridge compared alemtuzumab with interferon beta 1a, the most common drug used to treat MS.In both trials, alemtuzumab appeared to increase the risk of certain autoimmune disorders, particularly those affecting the thyroid.Disability rates were 13 percent among those in the alemtuzumab group and 20 percent of those in the interferon beta 1a group. The first trial found no significant difference in disability rates between the two groups of patients.
...MS occurs when the body's immune system starts to attack the coating of nerve fibers. 

Alemtuzumab, which is used to treat leukemia and other cancers of the immune system, works by altering the number, proportions and functions of certain types of lymphocytes, which are white blood cells that play a major role in the functioning of the immune system.There is no cure for MS, and existing drugs only aim to reduce the symptoms of the disease.

tags:the cancer,MS,immune system